Trial Profile
Extension Study for BAY43-9006 in Japanese Patients With Renal Cell Carcinoma [EXTENSION OF 700009408]
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Mar 2014
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Sponsors Bayer
- 24 Mar 2014 New trial record